Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
Results of Combination “Triplet” of Tucatinib with Trastuzumab and Capecitabine Published in The Lancet Oncology Results of Tucatinib in Combination with Ado-trastuzumab Emtansine Published in JAMA Oncology BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 11, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed- -First Patient Dosed in Phase 3 Global Confirmatory Trial- BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jul. 9, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 28, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
-Tisotumab Vedotin to be Evaluated as a Monotherapy in Patients Who Have Relapsed or Progressed After Standard of Care Treatment- -Tisotumab Vedotin Represents Fourth Late-Stage Development Program Added to List of Ongoing Pivotal Trials Along with Enfortumab Vedotin and Tucatinib- BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 6, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time . The presentation will be webcast live and
View HTML
Toggle Summary Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
Data Continue to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma Results from Patients Treated in North America Demonstrate Two-Year Modified Progression-Free Survival of 84.3 Percent in the ADCETRIS
View HTML
Toggle Summary Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jun. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc.
View HTML
Toggle Summary Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
BOTHELL, Wash. --(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey , M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc.
View HTML
Toggle Summary Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting in Chicago, Illinois ,
View HTML
Toggle Summary Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
BOTHELL, Wash. --(BUSINESS WIRE)--May 2, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m. Pacific Time . The presentation will be webcast live and available
View HTML